Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of different doses of Venus association in the treatment of vulvovaginal candidiasis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05031481
Study type Interventional
Source EMS
Contact
Status Withdrawn
Phase Phase 2
Start date July 1, 2022
Completion date March 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05012852 - Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis N/A
Completed NCT02150655 - Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Phase 0
Completed NCT00755053 - Comparative Efficacy of Ovule vs Tablet Phase 3
Completed NCT02679456 - Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Phase 2
Completed NCT02242695 - Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Phase 4
Recruiting NCT06397248 - DeVEnIR: Defining Vulvovaginal Candidiasis - Elements of Infection and Remedy
Completed NCT00895453 - Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) N/A
Completed NCT05327192 - VVC Sampling Study for Analysis Validation
Completed NCT05399641 - Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis Phase 3
Completed NCT01806623 - The Study Of Fluconazole For Vulvovaginal Candidiasis Phase 3
Recruiting NCT05079711 - Comparative Performance of a Vaginal Yeast Test
Completed NCT05507333 - Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis N/A
Completed NCT01144286 - Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Phase 2
Completed NCT00353561 - Diabetes Mellitus and Vulvovaginal Candidiasis Phase 3
Recruiting NCT05895162 - Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis. N/A
Not yet recruiting NCT06450990 - Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection Phase 1/Phase 2
Recruiting NCT05908682 - Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Completed NCT02203942 - Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis N/A
Completed NCT01926028 - Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Phase 1/Phase 2
Completed NCT00194324 - Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Phase 4